Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.

Cannavò S, Squadrito S, Curtò L, Almoto B, Trimarchi F

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme1 Oct 2001Cited by 16 (Europe PMC)

PMID11607883DOI10.1055/s-2001-17910PepBankPUB-11607883

Publisher page PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In untreated acromegaly, GH was 27.2 +/- 12.1 ng/ml after the first trimester of lanreotide, without a significant decrease.
In plain wordsIn untreated acromegaly, lanreotide did not significantly reduce growth hormone during the first trimester.
Peptide
Lanreotide
Outcome
No significant changeGH after first trimester, untreated group
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 14 days for three months, then every 10 days until month 6 · 3 monthsAs given in this study (human).
Measurements
Serum GH, end of 1st trimester (mean)
27.2 ng/ml
group 2 (10 patients, SRL before surgery)
Serum GH, end of 1st trimester (+/- value)
12.1 ng/ml
group 2 (10 patients, SRL before surgery)
Source sentences
Summary
Group 2 serum GH and IGF-1 levels were not significantly decreased at the end of the 1st trimester (GH: 27.2 +/- 12.1 ng/ml, NS.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty untreated acromegalics were enrolled randomly in two groups.
Summary · context
Only one of them was cured by surgery, whereas the other nine were treated with SRL.
Summary · context
In the other ten patients (group 2: 3 males and 7 females aged 43.2 +/- 12.3 years), transsphenoidal surgery followed SRL treatment.
Summary · context
SRL 30 mg was administered every 14 days for three months and then every 10 days until the 6th month.
Report a problemFND-1160788306
02HumanNon-randomized trialEfficacy outcome
In untreated acromegaly, IGF-1 was 698 +/- 74 ng/ml after the first trimester of lanreotide, without a significant decrease.
In plain wordsIn untreated acromegaly, lanreotide did not significantly reduce IGF-1 during the first trimester.
Peptide
Lanreotide
Outcome
No significant changeIGF-1 after first trimester, untreated group
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 14 days for three months, then every 10 days until month 6 · 3 monthsAs given in this study (human).
Measurements
Serum IGF-1, end of 1st trimester (mean)
698 ng/ml
group 2 (10 patients, SRL before surgery)
Serum IGF-1, end of 1st trimester (+/- value)
74 ng/ml
group 2 (10 patients, SRL before surgery)
Source sentences
Summary
IGF-1: 698 +/- 74 ng/ml, NS), whereas only serum IGF-1 (570 +/- 69 ng/ml, p < 0.05) was significantly reduced during the 2nd trimester of SRL (GH: 22.4 +/- 9.7 ng/ml, NS).
5 context sentences(design, population, supporting numbers)
Summary · context
Group 2 serum GH and IGF-1 levels were not significantly decreased at the end of the 1st trimester (GH: 27.2 +/- 12.1 ng/ml, NS.
Summary · context
Twenty untreated acromegalics were enrolled randomly in two groups.
Summary · context
Only one of them was cured by surgery, whereas the other nine were treated with SRL.
Summary · context
In the other ten patients (group 2: 3 males and 7 females aged 43.2 +/- 12.3 years), transsphenoidal surgery followed SRL treatment.
Summary · context
SRL 30 mg was administered every 14 days for three months and then every 10 days until the 6th month.
Report a problemFND-1160788307
03HumanNon-randomized trialEfficacy outcome
In untreated acromegaly, GH was 22.4 +/- 9.7 ng/ml during the second trimester of lanreotide, without a significant decrease.
In plain wordsIn untreated acromegaly, lanreotide did not significantly reduce growth hormone during the second trimester.
Peptide
Lanreotide
Outcome
No significant changeGH after second trimester, untreated group
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 14 days for three months, then every 10 days until month 6 · 6 monthsAs given in this study (human).
Measurements
Serum GH, 2nd trimester (mean)
22.4 ng/ml
group 2 (10 patients, SRL before surgery)
Serum GH, 2nd trimester (+/- value)
9.7 ng/ml
group 2 (10 patients, SRL before surgery)
Source sentences
Summary
IGF-1: 698 +/- 74 ng/ml, NS), whereas only serum IGF-1 (570 +/- 69 ng/ml, p < 0.05) was significantly reduced during the 2nd trimester of SRL (GH: 22.4 +/- 9.7 ng/ml, NS).
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty untreated acromegalics were enrolled randomly in two groups.
Summary · context
Only one of them was cured by surgery, whereas the other nine were treated with SRL.
Summary · context
In the other ten patients (group 2: 3 males and 7 females aged 43.2 +/- 12.3 years), transsphenoidal surgery followed SRL treatment.
Summary · context
SRL 30 mg was administered every 14 days for three months and then every 10 days until the 6th month.
Report a problemFND-1160788308
04HumanNon-randomized trialEfficacy outcome
In untreated acromegaly, lanreotide reduced IGF-1 to 570 +/- 69 ng/ml during the second trimester (p < 0.05).
In plain wordsIn untreated acromegaly, lanreotide significantly reduced IGF-1 during the second trimester.
Peptide
Lanreotide
Outcome
DecreaseIGF-1 after second trimester, untreated group
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 14 days for three months, then every 10 days until month 6 · 6 monthsAs given in this study (human).
Measurements
Serum IGF-1, 2nd trimester (mean)
570 ng/ml
group 2 (10 patients, SRL before surgery)
Serum IGF-1, 2nd trimester (+/- value)
69 ng/ml
group 2 (10 patients, SRL before surgery)
p value
< 0.05 none
group 2 (10 patients, SRL before surgery)
Source sentences
Summary
IGF-1: 698 +/- 74 ng/ml, NS), whereas only serum IGF-1 (570 +/- 69 ng/ml, p < 0.05) was significantly reduced during the 2nd trimester of SRL (GH: 22.4 +/- 9.7 ng/ml, NS).
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty untreated acromegalics were enrolled randomly in two groups.
Summary · context
Only one of them was cured by surgery, whereas the other nine were treated with SRL.
Summary · context
In the other ten patients (group 2: 3 males and 7 females aged 43.2 +/- 12.3 years), transsphenoidal surgery followed SRL treatment.
Summary · context
SRL 30 mg was administered every 14 days for three months and then every 10 days until the 6th month.
Report a problemFND-1160788309
05HumanNon-randomized trialEfficacy outcome
In untreated acromegaly, GH and IGF-I reached normal ranges in one patient after the second trimester of lanreotide.
In plain wordsIn untreated acromegaly, one patient had normal growth hormone and IGF-I after the second trimester of lanreotide.
Peptide
Lanreotide
Outcome
Not applicableGH and IGF-I normalization, untreated group
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 14 days for three months, then every 10 days until month 6 · 6 monthsAs given in this study (human).
Measurements
Patients with GH and IGF-I in normal range
1 patients
group 2 (10 patients, SRL before surgery), end of 2nd trimester
Source sentences
Summary
Serum GH and IGF-I fell in the normal range in 4 patients in group 1 and one in group 2 at the end of the second trimester of SRL therapy.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty untreated acromegalics were enrolled randomly in two groups.
Summary · context
Only one of them was cured by surgery, whereas the other nine were treated with SRL.
Summary · context
In the other ten patients (group 2: 3 males and 7 females aged 43.2 +/- 12.3 years), transsphenoidal surgery followed SRL treatment.
Summary · context
SRL 30 mg was administered every 14 days for three months and then every 10 days until the 6th month.
Report a problemFND-1160788311
06HumanNon-randomized trialEfficacy outcome
In postoperative acromegaly, lanreotide reduced GH to 17.6 +/- 5.4 ng/ml at the first trimester (p < 0.05).
In plain wordsIn postoperative acromegaly, lanreotide significantly reduced growth hormone during the first trimester.
Peptide
Lanreotide
Outcome
DecreaseGH after first trimester, postoperative group
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 14 days for three months, then every 10 days until month 6 · 3 monthsAs given in this study (human).
Measurements
Serum GH, end of 1st trimester (mean)
17.6 ng/ml
postoperative group 1 (9 patients treated with SRL)
Serum GH, end of 1st trimester (+/- value)
5.4 ng/ml
postoperative group 1 (9 patients treated with SRL)
p value
< 0.05 none
postoperative group 1 (9 patients treated with SRL)
Source sentences
Summary
In group 1, a significant decrease of serum GH, but not of IGF-1 levels, was achieved at the end of 1st trimester of SRL (GH: 17.6 +/- 5.4 ng/ml, p < 0.05.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty untreated acromegalics were enrolled randomly in two groups.
Summary · context
Only one of them was cured by surgery, whereas the other nine were treated with SRL.
Summary · context
In the other ten patients (group 2: 3 males and 7 females aged 43.2 +/- 12.3 years), transsphenoidal surgery followed SRL treatment.
Summary · context
SRL 30 mg was administered every 14 days for three months and then every 10 days until the 6th month.
Report a problemFND-1160788301
07HumanNon-randomized trialEfficacy outcome
In postoperative acromegaly, IGF-1 was 540 +/- 48 ng/ml after the first trimester of lanreotide, without a significant reduction.
In plain wordsIn postoperative acromegaly, lanreotide did not significantly reduce IGF-1 during the first trimester.
Peptide
Lanreotide
Outcome
No significant changeIGF-1 after first trimester, postoperative group
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 14 days for three months, then every 10 days until month 6 · 3 monthsAs given in this study (human).
Measurements
Serum IGF-1, end of 1st trimester (mean)
540 ng/ml
postoperative group 1 (9 patients treated with SRL)
Serum IGF-1, end of 1st trimester (+/- value)
48 ng/ml
postoperative group 1 (9 patients treated with SRL)
Source sentences
Summary
IGF-1: 540 +/- 48 ng/ml, NS), whereas a significant decrease in both GH and IGF-1 values was evident during the 2nd trimester (GH: 6.1 +/- 3.0 ng/ml, p < 0.05.
5 context sentences(design, population, supporting numbers)
Summary · context
In group 1, a significant decrease of serum GH, but not of IGF-1 levels, was achieved at the end of 1st trimester of SRL (GH: 17.6 +/- 5.4 ng/ml, p < 0.05.
Summary · context
Twenty untreated acromegalics were enrolled randomly in two groups.
Summary · context
Only one of them was cured by surgery, whereas the other nine were treated with SRL.
Summary · context
In the other ten patients (group 2: 3 males and 7 females aged 43.2 +/- 12.3 years), transsphenoidal surgery followed SRL treatment.
Summary · context
SRL 30 mg was administered every 14 days for three months and then every 10 days until the 6th month.
Report a problemFND-1160788302
08HumanNon-randomized trialEfficacy outcome
In postoperative acromegaly, lanreotide reduced GH to 6.1 +/- 3.0 ng/ml during the second trimester (p < 0.05).
In plain wordsIn postoperative acromegaly, lanreotide significantly reduced growth hormone during the second trimester.
Peptide
Lanreotide
Outcome
DecreaseGH after second trimester, postoperative group
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 14 days for three months, then every 10 days until month 6 · 6 monthsAs given in this study (human).
Measurements
Serum GH, 2nd trimester (mean)
6.1 ng/ml
postoperative group 1 (9 patients treated with SRL)
Serum GH, 2nd trimester (+/- value)
3 ng/ml
postoperative group 1 (9 patients treated with SRL)
p value
< 0.05 none
postoperative group 1 (9 patients treated with SRL)
Source sentences
Summary
IGF-1: 540 +/- 48 ng/ml, NS), whereas a significant decrease in both GH and IGF-1 values was evident during the 2nd trimester (GH: 6.1 +/- 3.0 ng/ml, p < 0.05.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty untreated acromegalics were enrolled randomly in two groups.
Summary · context
Only one of them was cured by surgery, whereas the other nine were treated with SRL.
Summary · context
In the other ten patients (group 2: 3 males and 7 females aged 43.2 +/- 12.3 years), transsphenoidal surgery followed SRL treatment.
Summary · context
SRL 30 mg was administered every 14 days for three months and then every 10 days until the 6th month.
Report a problemFND-1160788303
09HumanNon-randomized trialEfficacy outcome
In postoperative acromegaly, lanreotide reduced IGF-1 to 433 +/- 74 ng/ml during the second trimester (p < 0.02).
In plain wordsIn postoperative acromegaly, lanreotide significantly reduced IGF-1 during the second trimester.
Peptide
Lanreotide
Outcome
DecreaseIGF-1 after second trimester, postoperative group
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 14 days for three months, then every 10 days until month 6 · 6 monthsAs given in this study (human).
Measurements
Serum IGF-1, 2nd trimester (mean)
433 ng/ml
postoperative group 1 (9 patients treated with SRL)
Serum IGF-1, 2nd trimester (+/- value)
74 ng/ml
postoperative group 1 (9 patients treated with SRL)
p value
< 0.02 none
postoperative group 1 (9 patients treated with SRL)
Source sentences
Summary
IGF-1: 433 +/- 74 ng/ml, p < 0.02).
5 context sentences(design, population, supporting numbers)
Summary · context
IGF-1: 540 +/- 48 ng/ml, NS), whereas a significant decrease in both GH and IGF-1 values was evident during the 2nd trimester (GH: 6.1 +/- 3.0 ng/ml, p < 0.05.
Summary · context
Twenty untreated acromegalics were enrolled randomly in two groups.
Summary · context
Only one of them was cured by surgery, whereas the other nine were treated with SRL.
Summary · context
In the other ten patients (group 2: 3 males and 7 females aged 43.2 +/- 12.3 years), transsphenoidal surgery followed SRL treatment.
Summary · context
SRL 30 mg was administered every 14 days for three months and then every 10 days until the 6th month.
Report a problemFND-1160788304
10HumanNon-randomized trialEfficacy outcome
In postoperative acromegaly, GH was significantly lower during the second than the first trimester of lanreotide (p < 0.05).
In plain wordsIn postoperative acromegaly, growth hormone was lower during the second than the first trimester of lanreotide.
Peptide
Lanreotide
Outcome
DecreaseGH second versus first trimester, postoperative group
Study
n = 9
Comparator
first trimester of lanreotide
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 14 days for three months, then every 10 days until month 6 · 6 monthsAs given in this study (human).
Measurements
p value
< 0.05 none
postoperative group 1 (9 patients treated with SRL), 2nd vs 1st trimester
Source sentences
Summary
Serum GH levels, measured during the 2nd trimester of SRL therapy, were also significantly lower than levels measured at the end of the 1st trimester (p < 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty untreated acromegalics were enrolled randomly in two groups.
Summary · context
Only one of them was cured by surgery, whereas the other nine were treated with SRL.
Summary · context
In the other ten patients (group 2: 3 males and 7 females aged 43.2 +/- 12.3 years), transsphenoidal surgery followed SRL treatment.
Summary · context
SRL 30 mg was administered every 14 days for three months and then every 10 days until the 6th month.
Report a problemFND-1160788305
11HumanNon-randomized trialEfficacy outcome
In postoperative acromegaly, GH and IGF-I reached normal ranges in 4 patients after the second trimester of lanreotide.
In plain wordsIn postoperative acromegaly, four patients had normal growth hormone and IGF-I after the second trimester of lanreotide.
Peptide
Lanreotide
Outcome
Not applicableGH and IGF-I normalization, postoperative group
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 14 days for three months, then every 10 days until month 6 · 6 monthsAs given in this study (human).
Measurements
Patients with GH and IGF-I in normal range
4 patients
postoperative group 1 (9 patients treated with SRL), end of 2nd trimester
Source sentences
Summary
Serum GH and IGF-I fell in the normal range in 4 patients in group 1 and one in group 2 at the end of the second trimester of SRL therapy.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty untreated acromegalics were enrolled randomly in two groups.
Summary · context
Only one of them was cured by surgery, whereas the other nine were treated with SRL.
Summary · context
In the other ten patients (group 2: 3 males and 7 females aged 43.2 +/- 12.3 years), transsphenoidal surgery followed SRL treatment.
Summary · context
SRL 30 mg was administered every 14 days for three months and then every 10 days until the 6th month.
Report a problemFND-1160788310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.